

SAXSANA-NEWSLETTER

nº 1 (01/2021)

Dr. S. Hartmann

Dear AXSANA study sites,

We are proud to present to you the first international AXSANA newsletter. With this newsletter, we will inform you regularly about the current state of the study.

You can also find important information and files for download at out website: http://axsana.eubreast.com

We wish you all the best for the New Year 2021!

In the name of the International Steering Committee and the Organizing Comittee,

Mina

Dr. O. Gentilini

Prof. T. Kühn

PD Dr. M. Banys-Paluchowski

Ass. Prof. J. de Boniface Prof. E. Stickeler


Protocol amendment

Initially, only patients with histologically or cytologically confirmed lymph node metastasis were allowed to participate in AXSANA. Since core biopsy/FNA of suspicious nodes is standard in some countries but not in others, an amendment has been prepared after discussing this issue in the International Steering Board meeting. Now, patients with highly suspicious nodes upon imaging can be enrolled in AXSANA even if they have not received a minimally invasive biopsy of the node(s).


The amended protocol has been submitted to ethical committees and already approved in some countries (Greece, Romania, Switzerland). Your National Steering Committee will provide you with the current version of the protocol approved in your country.

Quality of life (Qol)


- **IMPORTANT:** Keep in mind that patients need to complete their baseline QoL questionnaires within 4 weeks before surgery. Example: surgery is scheduled for Jan, 14th \rightarrow baseline questionnaires should be completed between Dec, 17th and Jan, 13th.



The Swedish QoL team led by Jana de Boniface (Matilda Appelgren, Cristofer Lagerros, Helena Sackey) is working at full speed to establish the online QoL tool. We hope that AXSANA patients will be able to use the tool in February 2021. From then on, study sites will only have to print the QoL access data and give them to the patient. We will inform you as soon as we are online!



Enrollment status



	Enrolled patients	First site open
Total	123	August 2020

AXSANA Initiation presentation

The study sites are kindly asked to participate in an initiation presentation. The next international initiation presentation in English will take place on January, 25th 2021 (Monday) at 4 p.m. CET (Time Zone Berlin, Paris, Madrid, Rome). Zoom link: <u>https://us02web.zoom.us/j/86193865170</u>

You can also visit our website to see the recorded initiation videoconference at: <u>http://axsana.eubreast.com</u>

San Antonio Breast Cancer Symposium 2020

The concept of the AXSANA study has been presented at several national conferences and recently in the "Ongoing Trials" session at the SABCS 2020:

EUROPEAN BREAST CANCER RESEARCH ASSOCIATION OF SURGICAL TRIALISTS	6 AXSANA	BREAST STUDY GROUP AWOgy FILE SHOULD THE SHO
	AXillary Surgery After NeoAdjuvant cohort study of the EUBREAST study group ode-positive breast cancer patients treated wi	to evaluate different surgical methods of axillary staging
Maggie Banys-Paluchowski ¹ , Elmar Stickeler ² , Jana de Boniface ³ , Ores	te Gentilini ⁴ , Marc Thill ⁵ , Steffi Hartmann ⁶ , Marina Mangold ⁷ , Christine Thorsten Kühn ¹³ , on behalf of EUBREAST study g	Solbach ⁸ , Jens-Uwe Blohmer ⁹ , Michael Untch ¹⁰ , Matilda Appelgren ¹¹ , Hans-Christian Kolberg ¹² , roup
Maggie Banys-Paluchowski ¹ , Elmar Stickeler ² , Jana de Boniface ³ , Ores BACKGROUND		

HRQOL (evaluated using 4 standardiz

questionnaires [EORTC QLQ-C 30, BR

23, Lymph ICF and SOC-13] at baseline

Secondary endpoints are the feasibility and performance of different axillary

staging techniques (detection rate, number of removed lymph nodes and associatio

and 1, 3, 5 years after surgery)

tandards in different countries

International AXSANA Teams

Country	National Steering Committee (Head of the NSC underlined in case of more than one member)
Austria	Prof. Florentia Peintinger
Finland	Dr. Laura Niinikoski, Dr. Tuomo Meretoja, Dr. Marjut Leidenius
France	Prof. Jean-Marc Classe, Prof. Emmanuel Barranger
Germany	PD Dr. M. Banys-Paluchowski, Dr. S. Hartmann, Prof. M. Thill
Greece	<u>Prof. Michalis Kontos</u> , Dr. Makis Kanavidis
Hungary	Dr. habil. Zoltan Matrai
Italy	<u>Dr. Oreste Gentilini</u> , Dr. Rosa di Micco
Norway	Dr. Ellen Schlichting
Poland	Prof. Dawid Murawa
Portugal	<u>Dr. David Pinto</u> , Prof. Maria Joao Cardoso
Romania	Dr. Eduard-Alexandru Bonci
Russia	Prof. Petr Krivorotko, Dr. A. S. Emelyanov
Spain	<u>Dr. Isabel Rubio</u> , Dr. Antonio Esgueva
Sweden	Prof. Jana de Boniface, Hanna Karlsson, Matilda Appelgren
Switzerland	Dr. Maria Luisa Gasparri
Turkey	Prof. Güldeniz Karadeniz Cakmak, Dr. U. Ugurlu, Dr. A. Sezer

Various forms of axillary staging surgery after NACT are currently in use internationally with the aim to ensure oncological safety and to avoid over-therapy (ALND, TLNB, TAD, SLNB) [1]. The choice of the appropriate technique generally depends on the national and international recommendations and europende for the properties of the appropriate technique generally depends on the national and international recommendations and europende for the properties of the appropriate technique generally depends on the national and international recommendations and europende for the properties of the appropriate technique generally depends on the national and international recommendations and europende for the properties of the propert

SLNB) [1]. The choice of the appropriate technique generally depends on the national and international recommendations and surgeon's preference. So far, no comparative data on the oncological outcome or the morbidity of the different procedures are available. Further research is needed to safely de-escalate the extent of axillary surgery in this patient group.



de metastasis prior to NACT (ycN0; right). RENCES

-Paluchowski et al. Arch Gynecol Obster 2020, Axillary ultrasound for prediction of respo

eoadjuvant therapy in the context of surgical strategies to axillary dissection...

For more information visit axsana.eubreast.com

This presentation is the intellectual property of the author/presenter. Contact them at <u>m.banys@outlook.com</u> for permission to reprint and/or distribute. ns of Gynecology, Asklepios Klinik Barmbek, Hamburg, Germany, ² Department of Gynecology and Obstetrics, Uniklinik RWTH Aachen, Aachen, Germany, ³ Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Surgery, Capio SL Gön tockholm, Sweden, ⁴ San Raffaele Hospital, Milan, Italy, ⁶ Department of Gynecology and Gynecology and Gynecology, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany, ⁸ Department of Gynecology and Obstetrics, Klinikum Südstadt Rostock, University of Rost termany, ¹ Esculape - Glinical Research Profession, Gladembach, Germany, ³ Breast Cancer Center, University Hospital, Goethe-University, Frankfurt am Main, Germany, ⁹ Department of Gynecology and Obstetrics, Klinikum Sudstadt Rostock, University of Rost termany, ¹ Esculape - Glinical Research Profession, Gladembach, Germany, ¹ Bepartment of Gynecology and Destrics, Klinikum Sudstadt Rostock, University, Frankfurt am Main, Germany, ⁹ Department of Gynecology and Destetrics, Klinikum Sudstadt Rostock, University of Rost termany, ¹ Sudstadt, Beirin, Germany, ¹ Warolinski Institutet, Stockholm, Sweden, ¹⁹ Department of Gynecology and Obstetrics, Mainhory Esculaped, Germany, ¹⁰ Department of Gynecology and Destetrics, Klinikum Eskingen, Germany, ¹⁰ Department of Gynecology and Destetrics, Klinikum Eskingen, Germany, ¹⁰ Department of Gynecology and Destetrics, Klinikum Eskingen, Germany, ¹⁰ Department of Gynecology and Destetrics, Klinikum Eskingen, Germany, ¹⁰ Department of Gynecology and Destetrics, Klinikum Eskingen, Germany, ¹⁰ Destetrics, Klinikum Eskingen, Germa

IMPRESSUM

EUBREAST Study Group Chairs and Co-Chairs: EUBREAST Prof. T. Kühn, Prof. E. Stickeler, Prof. J. de Boniface, Dr. O. Gentilini **Organizing Committee:** PD Dr. M. Banys-Paluchowski: m.banys@outlook.com Dr. S. Hartmann: steffi.hartmann@kliniksued-rostock.de Prof. T. Kühn: t.kuehn@klinikum-esslingen.de **International study coordination:** Ms. A. Jursik, Ms. J. Shabbir und Dr. M. Mangold a.jursik@klinikum-esslingen.de j.shabbir@klinikum-esslingen.de Tel. +49 711 3103 3064, Fax +49 711 3103 3069 In case of questions do not hesitate to contact your **National Steering Committee!**





GO-B

CLAUDIA VON SCHILLING

